
[Congressional Bills 113th Congress]
[From the U.S. Government Printing Office]
[H.R. 1366 Introduced in House (IH)]

113th CONGRESS
  1st Session
                                H. R. 1366

To direct the Commissioner of Food and Drugs to modify the approval of 
any drug containing controlled-release oxycodone hydrochloride to limit 
such approval to use for the relief of severe-only instead of moderate-
                to-severe pain, and for other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             March 21, 2013

 Mr. Lynch (for himself, Mr. Fitzpatrick, Mr. Rogers of Kentucky, Mr. 
   Rahall, Mr. Keating, Mr. Wolf, and Ms. Slaughter) introduced the 
   following bill; which was referred to the Committee on Energy and 
                                Commerce

_______________________________________________________________________

                                 A BILL


 
To direct the Commissioner of Food and Drugs to modify the approval of 
any drug containing controlled-release oxycodone hydrochloride to limit 
such approval to use for the relief of severe-only instead of moderate-
                to-severe pain, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Stop Oxy Abuse Act of 2013''.

SEC. 2. LIMITING APPROVAL OF DRUGS CONTAINING CONTROLLED-RELEASE 
              OXYCODONE HYDROCHLORIDE TO USE FOR RELIEF OF SEVERE-ONLY 
              PAIN.

    (a) In General.--Not later than 90 days after the date of the 
enactment of this Act, the Commissioner of Food and Drugs shall take 
such actions as may be necessary--
            (1) to modify the approval of any drug containing 
        controlled-release oxycodone hydrochloride under section 505 of 
        the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) to 
        limit such approval to use for the relief of severe-only 
        instead of moderate-to-severe pain; and
            (2) to limit any subsequent approval of a drug containing 
        controlled-release oxycodone hydrochloride under such section 
        to use for the relief of severe-only pain.
    (b) Applicability.--Any modification required by subsection (a)(1) 
shall apply to drugs introduced or delivered for introduction into 
interstate commerce on or after the date that is 180 days after the 
date of the enactment of this Act.
                                 <all>
